This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PT112, PT 112
Description: PT-112 is a novel small molecule member of the phosphaplatin family.
Phosplatin and SciClone
In August 2015, Phosplatin granted a regional license for its platinum agent, PT-112, to a U.S. based pharmaceutical company with extensive operations in China (the partner) for development and commercialization in China and certain adjacent territories. The agreement grants the partner the rights to develop and market PT-112 in Greater China for use in the treatment of oncology indications.
Under the terms of the agreement, Phosplatin has granted its partner exclusive development and commercialization rights to PT-112 in China, as well as the Hong Kong SAR, the Macau SAR, and Vietnam. The partner also has options to add Taiwan and South Korea to the territories covered by the agreement. In exchange, Phosplatin is eligible to receive upfront and milestone payments as well as tiered royalties based on commercial sales in the territory.
In September 2016, SciClone confirmed they obtained exclusive development and commercialization...See full deal structure in Biomedtracker
Partners: SciClone Pharmaceuticals, Inc.
Additional information available to subscribers only: